News

Strategic Offering by RiverNorth/DoubleLine Fund Enhances Shareholder Value

Strategic Offering by RiverNorth/DoubleLine Fund Enhances Shareholder Value

RiverNorth/DoubleLine Strategic Opportunity Fund Unveils New Rights Offering

RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (the “Fund”) has recently announced an exciting development intended to enhance shareholder value. The Board of Directors has authorized a non-transferable rights offering aimed at current stockholders, allowing them exclusive rights to purchase additional shares of common stock and newly issued 6.00%, 3-Year Term, Series C Term Preferred Stock.

Understanding the Offering Details

Information regarding this significant offering suggests that the Fund plans to apply for the listing of the Series C Preferred Stock on the New York Stock Exchange (NYSE) under the ticker OPPPRC. If approval is granted, trading is expected to commence shortly after the issuance date of the preferred shares.

Subscription Rights Explained

The Fund will distribute non-transferable subscription rights, or “Rights”, to stockholders of record, enabling them to acquire additional shares of common and preferred stock. Each Record Date Stockholder will receive one Right for each share they hold, with provisions that allow them to buy shares based on specific ratios. For example, for every six Rights, holders are eligible to purchase two new shares of common stock and one new share of Series C Preferred Stock.

Details of Rights Offering Terms

Significantly, the shares acquired through this offering will not grant rights to the immediate distributions scheduled for October or November 2024. However, full exercising of Rights will enable Record Date Stockholders to subscribe for more shares, known as “Over-Subscription Shares.” These additional shares will be allocated proportionally based on the stockholders’ original Rights.

Subscription Pricing Considerations

The subscription price for common stock will be determined by a formula, establishing a base price that will not be less than 90% of the net asset value or 95% of the market price, dependent on which is higher. It ensures fair pricing while accommodating market fluctuations. Meanwhile, the subscription price for the Series C Preferred Stock will be set at $10 per share.

Regulatory Framework and Next Steps

This rights offering will unfold in accordance with the Fund’s effective shelf registration statement filed with the Securities and Exchange Commission (SEC), which remains valid until mid-November 2024. Even though the existing shelf will expire during the offering, a replacement registration statement has already been filed to ensure ongoing compliance and to facilitate the offerings.

Investor Awareness and Education

It is vital for investors to comprehend the potential risks associated with this investment strategy. Common risks include the potential for low returns or even a loss of capital. To make informed investment decisions, prospective investors should thoroughly review the accompanying prospectus and understand the Fund's investment objectives, risks, charges, and expenses before engaging in stock purchases.

About RiverNorth Capital Management

Founded in the year 2000, RiverNorth is recognized for its adept management capabilities focused on opportunistic strategies in niche markets. With a deep understanding of market inefficiencies, RiverNorth manages various registered and private funds, striving towards optimal asset management and growth for its investors.

Frequently Asked Questions

What is the purpose of this rights offering?

This offering provides current stockholders the opportunity to purchase additional shares, enhancing their investment and potential returns.

How do the subscription rights work?

Each Record Date Stockholder receives rights based on their current holdings, allowing them to acquire more shares under specified terms.

What are the potential risks?

Investing carries inherent risks. Investors may receive little return or lose part or all of their investments.

Where will the new shares be listed?

The common stock and Series C Preferred Stock will trade on the NYSE with tickers OPP and OPPPRC, respectively.

How can investors get more information?

Investors should review the prospectus and consult their financial advisors for tailored advice regarding their investments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Stora Enso's Major Cross-Border Demerger Plan Unfolds

Updated Category News Views 88

A Grand Meeting with Serious Stakes The Board at Stora Enso Oyj is calling for an Extraordinary General Meeting (EGM) to tackle something massive—a cross-border partial demerger. Scheduled for December 15, 2026, this big pow-wow will take place in Helsinki, Finland. There’s a boatload of logistics in play, not least because it’s intended to split off their Swedish...

Continue Reading
Atrium's Heart Therapies: ATR 1072's Promising Data

Updated Category News Views 21

Atrium Therapeutics Strikes a Chord with New Data Tuning into the heartbeats of breakthrough developments, Atrium Therapeutics dropped some fresh, nonclinical insights about their latest contender, ATR 1072. This wasn't just any ordinary announcement; it's like when the market hears whispers of a Fed rate adjustment. The venue? The American Heart Association's 2026...

Continue Reading
ADC Therapeutics Preps Financial Results Release

Updated Category News Views 0

ADC Therapeutics: Eyes on the Financial Prize So here we are, folks—ADC Therapeutics is blitzing the stage and gearing up to spill the beans on their third-quarter saga come November 9, 2026. Who needs a crystal ball when you've got a press release to dissect every number and nuance? Anticipating the Numbers: What's at Stake? ADC Therapeutics has been riding the wave of...

Continue Reading
Isinwheel's 2027 E-Mobility Pitch: Beyond Resolutions

Updated Category News Views 163

Embracing the E-Mobility Shift Here we are at the tail end of 2026, and isinwheel is riding high on the wave of New Year resolutions with their hefty e-mobility lineup. It's not just about buying the gear—it's about tackling our reliance on gas-guzzlers with electric scooters and bikes as our trusty steeds. "Reduce car trips? More greenery in your commute? These aren't...

Continue Reading
Wujiang Celebrates 90 Years of Fei Xiaotong's Legacy

Updated Category News Views 118

If you thought anniversaries were just about looking back, think again! In Wujiang, November 1st was all about forging ahead. Scholars and local officials weren't just reminiscing about Fei Xiaotong's landmark field study at Jiangcun 90 years ago; they were strategizing how to apply the sociologist's insights to today's economic and community challenges. Marking a Legacy...

Continue Reading
German Court Backs Usmanov in Legal Standoff with EU

Updated Category News Views 44

Usmanov Scores a Win in German Courts The courtroom dramas play out yet again, and this time the spotlight's on Alisher Usmanov versus the European Union Council. It's a scene rich in bureaucratic fireworks, where Germany's Federal Court of Justice shined a beam of clarity amidst all that legal fog. They call it a 'landmark ruling'—a voice of reason brushing aside the...

Continue Reading
Fresenius, WuXi Biologics Blaze New Biosimilars Trail

Updated Category News Views 97

Fresenius Bets Big on Biopharma with WuXi Partnership A deal inked by Fresenius and WuXi Biologics is stirring up the biosimilars pot, aiming to widen Fresenius' grip on the market tenfold. We're not talking small potatoes here; we're talking up to 66 biosimilar molecules against a hefty backdrop of more than €370 billion in originator sales. It's as if they've said,...

Continue Reading
Sinopec Unveils Biodiversity Report at COP17

Updated Category News Views 47

Sinopec's First Step on the Global Biodiversity Stage Seems like Sinopec (HKG: 0386) has decided to toss its hat into the biodiversity conservation ring. At COP17 in Armenia, they released their inaugural Global Biodiversity Conservation Report—an event that marks more than just a company selling oil and gas. Now, they're talking wildlife and ecologies. Is that irony,...

Continue Reading
Bahrain's USD 3.89 Billion Investment Surge in 2026

Updated Category News Views 228

Bahrain's Bold Moves to Woo Global Investment Bahrain's never been one to tiptoe around, huh? With a whopping USD 3.89 billion on the line, the Kingdom's flashing its neon sign to investors: "Open for Business!" These Golden License projects aren't just a few shiny new ventures — they're bridging aviation logistics, real estate, and the tech sector. Talk about ambition....

Continue Reading
Muyang Group's High-Stakes Legal Battle Over Corporate Sabotage

Updated Category News Views 108

Decades of Corporate Drama Unfold in Court A pesky legal storm is brewing from the heart of Yangzhou, China, as Jiangsu Muyang Group battles former execs in a lawsuit that reeks of corporate intrigue. You can't make this stuff up—downright Shakespearean treachery unfolding at a feed machinery powerhouse! Muyang's courtroom escapades haven't exactly flown under the...

Continue Reading

Top 5 Most Recently Viewed Articles

Rural Healthcare Transformation: Data-Driven Innovations in Practice

Updated Category News Views 234

Revolutionizing Rural Healthcare with Data-Driven Solutions REDi Health Analytics, LLC ("REDi Health") has forged a partnership with a state health department to significantly boost the data capacity of six rural hospitals. Their goal is to enhance healthcare delivery and bridge the health disparities prevalent in rural communities. As highlighted by John Wadsworth,...

Continue Reading
Boeing Charges Union with Unfair Labor Practices Amid Strikes

Updated Category News Views 194

Boeing Takes Action Against Striking Union Boeing, a leading name in aerospace manufacturing, has recently initiated a charge of unfair labor practices against the union representing approximately 33,000 West Coast factory workers. This action highlights the ongoing tensions amid the strike that has disrupted operations. Allegations of Bad Faith Bargaining The charge was...

Continue Reading
Deckers Outdoor Adjusts to Split with New Price Target Set

Updated Category News Views 58

Deckers Outdoor Stock Price Target Update Recently, Evercore ISI made headlines by revising its price target for the shares of Deckers Outdoor (NYSE: DECK), adjusting it down to $183 from the previous level of $1,100. This reduction, while significant, comes after the company undertook a 6-for-1 stock split, a move aimed at making the stock more appealing to investors....

Continue Reading
Beam Therapeutics Welcomes Sravan Emany as New CFO

Updated Category News Views 247

Beam Therapeutics Welcomes a New Chief Financial Officer Beam Therapeutics Inc. (Nasdaq: BEAM), a leader in developing precision genetic medicines, is heralding an important new chapter in its journey with the appointment of Sravan K. Emany as its Chief Financial Officer (CFO). Bringing vast experience from his previous roles in well-established corporations, Mr. Emany is...

Continue Reading
Keysight Technologies Partners with UL Solutions for Certification

Updated Category News Views 192

Keysight Technologies, Inc. (NYSE: KEYS) made headlines by securing its role as a test partner for Thunderbolt 5 certification back in 2024. This partnership with UL Solutions is no small feat—it's a strategic play that puts Keysight squarely in the fast lane of advanced connectivity. As the landscape shifts, this collaboration hints at what’s coming: faster speeds...

Continue Reading